MYOK - Bristol Myers Squibb: The MyoKardia Acquisition Was Not A Bad Idea
- MYOK may have seemed an expensive and unwanted use of cash at first, but it couldn't have been too bad for management to have bought it.
- Indeed, successfully raising clinical awareness for HCM and R&D successes will have made the acquisition a good bargain.
- We can determine this with a market assessment based on BMY pricing power with Eliquis, which manages similar patient risks.
- Overall, the market has determined the MYOK price fair, and we see substantial upside from the acquisition if BMY executes.
For further details see:
Bristol Myers Squibb: The MyoKardia Acquisition Was Not A Bad Idea